InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
87.34
(
0.49%
)
Bitcoin
57,870.15
(
-3.81%
)
Post# of 252484
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

poorgradstudent

Send PM Follow Ignore
Followers 73
Posts 3426
Boards Moderated 1
Alias Born 04/28/2004

poorgradstudent

Re: rkrw post# 2417

Tuesday, 06/08/2004 10:14:07 AM

Tuesday, June 08, 2004 10:14:07 AM

Post# of 252484
Many Imclone investors are holding out hope that Erbitux is magical amongst the EGF-R inhibitors and will succeed where Iressa and Tarceva failed: 1st line NSCLC.

However, the activity of Erbitux in the refractory NSCLC setting is not an improvement over Iressa or Tarceva. Erbitux showed a 6% ORR. I'm skeptical that it will fare any different in the first line, unless IMCL/BMY/Merck KgAa adopt a novel treatment schedule.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up